Tag - IVA

Feature

Inventiva targeting MASH at its biological roots

Inventiva (Euronext Paris and Nasdaq: IVA) is advancing development of an oral treatment for metabolic dysfunction-associated steatohepatitis (MASH) with its investigational next-generation pan-peroxisome proliferator...

October 20, 2026

Executive Moves

Inventiva builds C-suite ahead of Phase 3 MASH readout

Inventiva (Euronext Paris and NASDAQ: IVA) has appointed three new members to its leadership team, including Axel-Sven Malkomes as chief financial officer, Susan Coles as chief legal officer, and Pamela Herbster as...

April 27, 2026

Developments

Inventiva odiparcil gets FDA fast track designation for mucopolysaccharidosis

Inventiva’s (PSE:IVA; NASDAQ:IVA) odiparcil received FDA fast track designation for the treatment of mucopolysaccharidosis (MPS) Type VI, a rare progressive genetic disorder. MPS is caused by deficient versions of the...

October 20, 2020

Tag - IVA

Inventiva targeting MASH at its biological roots

Inventiva builds C-suite ahead of Phase 3 MASH readout

Inventiva odiparcil gets FDA fast track designation for mucopolysaccharidosis

Subscribe